Newron Pharmaceuticals S.p.A. (SWX:NWRN)

Switzerland flag Switzerland · Delayed Price · Currency is CHF
14.34
+0.24 (1.70%)
Oct 21, 2025, 5:31 PM CET
1.70%
Market Cap281.45M
Revenue (ttm)55.93M
Net Income (ttm)23.65M
Shares Out19.96M
EPS (ttm)1.11
PE Ratio12.68
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume138,970
Average Volume203,365
Open14.00
Previous Close14.10
Day's Range13.68 - 14.58
52-Week Range5.20 - 16.00
Beta0.75
RSI61.87
Earnings DateDec 18, 2025

About Newron Pharmaceuticals

Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson’s in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company’s lead compound includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III cl... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1999
Employees 22
Stock Exchange SIX Swiss Exchange
Ticker Symbol NWRN
Full Company Profile

Financial Performance

Financial numbers in EUR Financial Statements